Siegfried and Novavax Extend their Collaboration
Novavax, a US-based biopharmaceutical company, and Siegfried have decided to extend their collaboration for the aseptic fill & finish of Novavax's protein-based coronavirus vaccine Nuvaxovid at Siegfried's manufacturing site in Hameln (Germany). The original manufacturing and supply agreement has started in 2021 with an original term until end of 2022 and has now been extended until the end of 2023.
September 28, 2022